Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504446 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
A Phase 2 study of Refractory or Unexplained Chronic Cough, sponsored by Nocion Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT06504446: Recruiting Phase 2 study of Refractory or Unexplained Chronic Cough, sponsored by Nocion Therapeutics.
NCT06504446 is a Phase 2 study of Refractory or Unexplained Chronic Cough that is actively recruiting participants, run by Nocion Therapeutics. The registered enrollment target is 455 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (242% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06504446, a Phase 2 study of Refractory or Unexplained Chronic Cough, is actively recruiting participants, sponsored by Nocion Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
Primary Outcome
Change in 24-hour Coughs per hour from Baseline will be based on VitaloJAK® Cough Counts. The VitaloJAK® is a 510(k)-cleared medical device consisting of a digital sound recorder with 2 microphones; a lapel air microphone attached to the participant's clothing and an adhesive chest wall microphone which is attached to the skin at the top of the sternum.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG NOC-110
Study Locations (20)
California
- So Cal Clinical Research - Huntington Beach
- Allergy and Asthma Associates of Southern California dba Southern California Research - Laguna Niguel
- Paradigm Clinical Research Centers, LLC - Modesto - Modesto
- NewportNativeMD,Inc - Newport Beach
- Center for Clinical Trials, LLC - Paramount
- Paradigm Clinical Research Centers, LLC - Redding
- DaVinci Research LLC. - Roseville
- Allergy & Asthma Associates of Santa Clara Valley - San Jose
- California Allergy & Asthma Medical Group Inc. - San Jose
- Allergy, Asthma, and Immunology Medical Group - Ventura
- Allergy and Asthma Clinical Research Inc - Walnut Creek
Florida
- Innovative Research of West Florida, Inc. - Clearwater
- Omega Research Debary, LLC - DeBary
- Jacksonville Center for Clinical Research - Jacksonville
- Clinical Site Partners, LLC Leesburg dba Flourish Research - Leesburg
Arizona
- Medical Research of Arizona - Scottsdale
- AMR Phoenix - Tempe
Alabama
- G & L Research, LLC - Foley
Arkansas
- Little Rock Allergy & Asthma, P.A. Clinical Research Center - Little Rock
Colorado
- Lynn Institute of Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2024-09-24 |
| Est. Completion | 2026-04-10 |
| Phase | Phase 2 |
What NCT06504446 shows while recruiting
NCT06504446 is an interventional study that assigns participants to a tested intervention. The registered 455 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (242% higher).
The record links to 1 condition, with Refractory or Unexplained Chronic Cough appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06504446 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06504446 about?
NCT06504446 is a clinical study titled "Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough". This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
What is the current status of trial NCT06504446?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 455 participants. The study started on 2024-09-24. Estimated completion is 2026-04-10.
What conditions does trial NCT06504446 study?
This clinical trial studies the following conditions: Refractory or Unexplained Chronic Cough.
What interventions are being tested in trial NCT06504446?
The interventions under investigation include: Placebo (OTHER), NOC-110 (DRUG).
Who is sponsoring clinical trial NCT06504446?
This trial is sponsored by Nocion Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504446 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06504446's enrollment target sits among peer trials
455 85th of 2000 higher than 1,915 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
- NCT06079346 · 455 participants · Phase 2
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- NCT06725030 · 455 participants
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
- NCT04462302 · 456 participants · NA
An Internet-based Program to Help Cancer Survivors Manage Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI